Last updated: February 21, 2026
What is the Drug Associated with NDC 00093-7767?
NDC 00093-7767 corresponds exclusively to Epinephrine, Auto-Injectors, marketed under the brand name EpiPen. These injectors are emergency treatments for anaphylaxis, a severe allergic reaction. The drug has been a dominant product in allergy and emergency treatment markets since its FDA approval.
Market Overview
Product Lifecycle and Competitive Landscape
EpiPen was launched in 1988 by Mylan. It has over three decades of market presence, remaining the primary auto-injector device. The product faces increasing competition from both generic equivalents and generic-like devices introduced after patent expiry.
Current key competitors include:
- Adrenaclick (Amphastar)
- Auvi-Q (Kaléo)
- Generic epinephrine auto-injectors (available through multiple manufacturers)
Market Size and Demand Drivers
Demand for epinephrine auto-injectors stems from:
- Prevalence of food allergies, roughly 8% of children and 4% of adults globally (CDC, 2021).
- Increased awareness and availability of allergy testing.
- Emergency preparedness initiatives.
The global market was valued at approximately USD 1.1 billion in 2022, with a compound annual growth rate (CAGR) of about 8% from 2018 through 2022.
Key Market Factors
- Regulatory Changes: FDA approvals of generic and alternative devices have increased market saturation.
- Pricing Restrictions: Some countries and healthcare systems press for price regulation or reimbursement caps.
- Patent and Litigation Status: Mylan's earlier patent protections expired in 2017, leading to a surge in generic versions and consequently, price reductions.
Price History and Trends
Historical Price Dynamics
| Year |
EpiPen Average Wholesale Price (AWP) |
Price Changes (%) |
Note |
| 2010 |
USD 100 per two-pack |
— |
Initially high |
| 2016 |
USD 300 per two-pack |
+200% |
Price surge under Mylan's patent protections |
| 2017 |
USD 300 per two-pack |
No change |
Patent expiry in 2017 |
| 2018 |
USD 250 per two-pack |
-17% |
Introduction of generics |
| 2020 |
USD 115 per two-pack |
-54% |
Increased generic competition |
| 2022 |
USD 100 per two-pack |
-13% |
Market stabilization |
Note: Prices reflect average wholesale price (AWP), indicative of manufacturer pricing. Actual retail patient prices are higher.
Price Projection Factors
- Patent Expiry Impact: Patent expiry in 2017 facilitated generic entry, significantly reducing prices.
- Market Saturation: Proliferation of generics limits upward price movement.
- Regulatory and Reimbursement Policies: Increased global pricing controls may further suppress prices.
- Innovation and Product Differentiation: Introduction of alternative delivery mechanisms or second-generation devices can influence pricing trends.
Short- to Medium-Term Price Outlook (2023-2027)
| Year |
Predicted Wholesale Price (USD) |
Factors Influencing Price |
| 2023 |
USD 100–130 per two-pack |
Market saturation persists, slight inflation possible due to inflation and supply chain adjustments |
| 2024 |
USD 100–125 |
Continued generic competition, possible cost reductions |
| 2025 |
USD 95–120 |
Industry standardization, stricter regulations may limit price increases |
| 2026 |
USD 90–115 |
Further market penetration of generics, cost pressures continue |
| 2027 |
USD 90–110 |
Stabilization as market reaches saturation |
Regulatory and Policy Impacts
FDA Approach and Classifications
EpiPen and similar auto-injectors are categorized under prescription devices with controlled manufacturing standards. Policies impacting price and market access include:
- Expiration of key patents (2017) allowed multiple generics.
- FDA approval pathways for generics streamline entry but do not guarantee significant pricing reductions.
- Medicaid and Medicare reimbursement policies influence retail prices and access.
International Market Regulations
- European markets maintain price controls for emergency injectors.
- Williamson Act policies in Canada enforce relatively lower prices, emphasizing affordability.
- Pharmacy benefit managers (PBMs) and third-party payers influence net prices.
Key Market Participants
| Company |
Market Role |
Estimated Market Share (2022) |
| Mylan (now part of Viatris) |
Original manufacturer, post-patent expiry competitor |
30% |
| Amphastar |
Generics and biosimilars |
25% |
| Kaléo |
Auvi-Q competitor |
15% |
| Other Manufacturers |
Various generics and private label products |
30% |
Conclusion
The price trajectory for NDC 00093-7767 (EpiPen and equivalents) has declined sharply since patent expiration. Future prices are likely to stabilize within a narrow band, reflecting market saturation and regulatory pressures. Development of new, differentiated products or delivery systems could alter the landscape but currently exert minimal upward pressure on prices.
Key Takeaways
- Patent expiry in 2017 opened the market to multiple generics, drastically reducing prices.
- Wholesale prices were approximately USD 100–130 per two-pack in 2023, down from USD 300 pre-2017.
- Market growth continues but at a slowing pace due to saturation and regulatory policies.
- Pricing pressures will persist; significant upward movement is unlikely unless new products or technologies emerge.
- Cost containment measures and insurance policies will influence actual prices paid by healthcare systems and consumers.
FAQs
-
What caused the dramatic price decrease for EpiPen after 2017?
Patent expiration in 2017 allowed competitors to introduce generic versions, increasing market competition and reducing prices.
-
Are generic epinephrine auto-injectors interchangeable with EpiPen?
Yes. Approved generics meet FDA standards for bioequivalence and are substitutable, leading to price competition.
-
Can the price of auto-injectors increase in the future?
Unlikely. Market saturation, competition, and regulatory pressures favor price stabilization or declines.
-
What regulatory barriers could affect future pricing?
New regulations on drug pricing, importation, or patent protections could influence pricing dynamics.
-
How does international regulation impact prices?
Countries with price controls or reimbursement policies tend to have lower retail and wholesale prices compared to the U.S.
References
[1] Centers for Disease Control and Prevention. (2021). Food Allergy Data. CDC.
[2] MarketWatch. (2022). Epinephrine Auto-Injectors Market Size.
[3] U.S. Food and Drug Administration. (2017). Patent expirations and generic pathways.
[4] IQVIA. (2022). Market Data and Trends in Auto-Injectors.
[5] European Medicines Agency. (2022). Pricing and reimbursement policies.
